Phosphodiesterase (PDE) Inhibitors

Phosphodiesterase (PDE) Inhibitors

Phosphodiesterase (PDE) Inhibitors are conventionally used to block enzyme phosphodiesterase, thus preventing the breakdown of cyclic adenosine monophosphate (cAMP), and cyclic guanosine monophosphate (cGMP), which act as very important second messengers in several cellular processes. PDE inhibitors are being used for the treatment of pulmonary hypertension, erectile dysfunction, cardiovascular disease, neurological diseases, and many more. The Consensus of Taiwan Society of Cardiology in May 2023 reported a prevalence of around 1-2% of heart failure in adults. The Centers for Disease Control and Prevention of the U.S. estimated that approximately 0.8 million people in the U.S. suffer from heart attack every year in May 2023. The phosphodiesterase (PDE) inhibitors market has seen a potential rise in gaining the inclination of healthcare organizations in the market. Apart from this many factors were responsible for propelling this market, like the rise in chronic diseases, the rise in clinical research, increased sedentary lifestyle leading to obesity, and a higher rate of pharmacy visits. For instance, as per the World Obesity Atlas 2022, estimations are such that 1 billion people worldwide, comprising one in five women and one in seven men will be suffering from obesity by the year 2030. Such factors have helped phosphodiesterase (PDE) inhibitors to substantially gain prevalence in the market.

The Phosphodiesterase (PDE) Inhibitors Market is expected to grow at a strong CAGR of 6.1% during the forecast period due to the rising pharmaceutical investment in the development of phosphodiesterase (PDE) inhibitors owing to which pharmaceutical companies have adopted strategic alliances to maintain a competitive edge in the global market. For instance, Pfizer completed the acquisition of Arena Pharmaceuticals in March 2022 with the aim of developing better treatment approaches for immuno-inflammatory diseases. Several other factors, increase in the geriatric population, initiatives for research and development activities, promising product pipeline and technological advancements are driving the growth of the market during the forecast period. According to World Health Organization (WHO), the share of people aged above 60 will rise to 1.4 billion by 2030 while this share will increase to 2.1 billion by 2050 which would be more than double the share of the geriatric population in the year 2020 i.e., 1 billion.

• Based on drug type, the market is segmented into specific, non-specific, and others. The specific drug type segment held the dominant share of the market in the year 2022 owing to its widespread use for treating erectile dysfunction and pulmonary hypertension-like diseases. Also known as phosphodiesterase (PDE) inhibitors, these drugs are designed to target particular PDE isozymes. PDE-5 among all specific PDE inhibitors held the maximum share in the market in the year 2022. These factors are supposed to drive the dominance of specific phosphodiesterase (PDE) inhibitors in the market. Likewise, there are several FDA-approved PDE5 inhibitors available in the market like sildenafil, vardenafil, tadalafil, and avanafil. Thus, the specific drug type segment held the dominant share of the market in the year 2022.
• By route of administration, the market is segmented into oral, parenteral, and others. The oral segment held the dominant share of the market in 2022 owing to the feasibility of consuming medicine in the form of tablets. Evidently, tablets are reported to be the most commonly used solid dosage forms among all medication forms, because of their advantages, ease in consumption, and increasing popularity. Multiple pharmaceutical companies are draining their funds and efforts to bring a potent solution to meet market demands. For instance, Dolo has reported making sales of Rs 567 crore since March 2020, selling more than 350 crore tablets. and 7.5 crore strips of medicine. Hence, the oral segment held the dominant share of the market in 2022.
• On the basis of application, the market is segmented into pulmonary hypertension, erectile dysfunction, neurological diseases, and others. The pulmonary hypertension segment held a significant share of the market in 2022 attributed to the rise in the prevalence of pulmonary diseases throughout the world. According to the American Journal of Managed Care pulmonary arterial hypertension is a rare disorder found in 15 to 50 persons per million within the U.S. and Europe. Also, according to the National Institute of Health, the mean prevalence of pulmonary arterial hypertension was 11.6 per million and the approximate incidence rate was 2.4 per million children per year in June 2020. Thus, the pulmonary hypertension segment held a significant share of the market in 2022.
• For a better understanding of the market adoption of the phosphodiesterase (PDE) inhibitors industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a significant share of the market. Several factors such as increasing healthcare expenditure, the surge in the prevalence of chronic diseases, and the presence of the majority of key players and their associated surge in the production of PDE inhibitors are driving the regional market. For instance, the American Heart Association reported in January 2023 that among the overall population, 77.5% of men and 75.4% of women have some form of cardiovascular disease in the U.S. Therefore, North America held a significant share of the market in the year 2022.
• Some of the major players operating in the market include Pfizer Inc.; Novartis AG; AbbVie Inc.; Dr. Reddy’s Laboratories Ltd.; Bristol-Myers Squibb Company; GSK plc.; Bayer AG; Teva Pharmaceuticals Industries Ltd.; Lilly; AstraZeneca.